The offering comprises 2,750,498 shares of ANAB common stock issued at $36.50 each. It was led by current investor, EcoR1 Capital, and included participation from both new and existing investors, including Cormorant Asset Management, Farallon Capital Management, First Light Asset Management, Woodline Partners LP, multiple large investment management firms, and Sanofi (SNY).

Sanofi (SNY) did not receive rights to any of Anaptys' programs as a part of their equity investment.

Anaptys (ANAB) intends to use the net proceeds of this offering primarily for general corporate purposes, which may include funding Phase 3 enabling activities for ANB032 and rosnilimab, working capital and general corporate purposes.

The offering is expected to close on or about Aug. 15, 2024, subject to the satisfaction of customary closing conditions.